Raheleh Roudi at University of Stanford, United States
Dr. Raheleh Roudi is a molecular medicine expert with extensive experience in drug discovery, cancer immunotherapy, and nanoparticle-based therapeutics. She is currently a Basic Life Research Scientist at Stanford University, where she focuses on iron oxide nanoparticle development, drug metabolism, and preclinical cancer models. Dr. Roudi has a strong background in molecular and cellular biology, in vivo pharmacology, and bioinformatics, with expertise in single-cell RNA sequencing, protein characterization, and immune profiling.
Publication Profile
scopus
shocular
orcid
Educational Details
- Ph.D. in Molecular Medicine, Iran University of Medical Sciences (2009-2014)
- MSc in Human Genetics, Tabriz University of Medical Sciences (2007-2009)
- B.A. in Midwifery, Tehran University of Medical Sciences (2001-2006)
Professional Experience
Dr. Roudi has a diverse research background spanning academia and biomedical research institutions. At Stanford University, she is involved in nanoparticle-based drug delivery, pharmacokinetics, and immune cell trafficking in tumor models. Previously, as a Postdoctoral Associate at the University of Minnesota, she investigated the molecular mechanisms of liver diseases and developed potential therapeutic agents using bioinformatics and preclinical models. As a Visiting Scientist at the University of Texas Health Science Center, she contributed to the development of iNETgrate, a Bioconductor package for integrating DNA methylation and gene expression data. During her tenure as a Lecturer and Researcher at Iran University of Medical Sciences, she worked extensively on cancer stem cell characterization, biomarker discovery, and targeted immunotherapies for solid tumors.
Research Interest
Dr. Roudi’s research focuses on translational cancer therapeutics, nanoparticle-based drug delivery, immune-oncology, and pharmacokinetics. She is particularly interested in preclinical drug evaluation, molecular mechanisms of disease, and the development of novel therapeutic strategies for cancer and liver diseases. Her expertise extends to in vivo imaging (MRI, BLI), flow cytometry, recombinant protein expression, and computational biology.
Top Noted Publication
1. Immune-related adverse events associated with PD-1 and PD-L1 inhibitors for non-small cell lung cancer: A PRISMA systematic review
Authors: X Sun, R Roudi, T Dai, S Chen, B Fan, H Li, Y Zhou, M Zhou, B Zhu, C Yin, et al.
Journal: BMC Cancer
Publication Year: 2019
Citations: 151
Summary:
- This systematic review assesses the immune-related adverse events (irAEs) caused by PD-1 and PD-L1 inhibitors in non-small cell lung cancer (NSCLC) treatment.
- It follows PRISMA guidelines to analyze clinical trials and real-world studies, offering insights into the safety profile of checkpoint inhibitors.
- The paper is widely cited due to its clinical relevance, guiding oncologists in managing irAEs in immunotherapy-treated patients.
2. Antimicrobial peptides as biologic and immunotherapeutic agents against cancer: A comprehensive overview
Authors: R Roudi, NL Syn, M Roudbary
Journal: Frontiers in Immunology
Publication Year: 2017
Citations: 145
Summary:
- This paper explores the role of antimicrobial peptides (AMPs) in cancer therapy, emphasizing their immunomodulatory and anti-tumor properties.
- It provides a detailed review of AMPs as potential biologic agents for immunotherapy, discussing their mechanisms of action, safety, and clinical applications.
- Its high citation count reflects the growing interest in alternative immunotherapeutic approaches beyond checkpoint inhibitors.
3. Differential expression of cancer stem cell markers ALDH1 and CD133 in various lung cancer subtypes
Authors: R Roudi, A Korourian, A Shariftabrizi, Z Madjd
Journal: Cancer Investigation
Publication Year: 2015
Citations: 95
Summary:
- Investigates the expression of ALDH1 and CD133, two key cancer stem cell markers, in different lung cancer subtypes.
- Provides insights into the heterogeneity of lung cancer and its implications for targeted therapies.
- This study is crucial for understanding cancer stem cell biology and developing novel therapeutic strategies.
4. Immunotherapy (excluding checkpoint inhibitors) for stage I to III NSCLC treated with surgery or radiotherapy with curative intent
Authors: J Zhu, Y Yuan, X Wan, D Yin, R Li, W Chen, C Suo, H Song, R Roudi
Journal: Cochrane Database of Systematic Reviews
Publication Year: 2021
Citations: 91
Summary:
- Systematic review assessing non-checkpoint immunotherapies, including dendritic cell-based therapies, cytokines, and cancer vaccines, for early-stage NSCLC.
- Highlights alternative immunotherapy approaches for patients ineligible for PD-1/PD-L1 inhibitors.
- A valuable reference for developing personalized immunotherapy regimens in lung cancer treatment.
5. Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced NSCLC: A meta-analysis
Authors: A Tartarone, G Roviello, R Lerose, R Roudi, M Aieta, P Zoppoli
Journal: Future Oncology
Publication Year: 2019
Citations: 83
Summary:
- Compares the efficacy and safety of anti-PD-1 (e.g., pembrolizumab, nivolumab) vs. anti-PD-L1 (e.g., atezolizumab, durvalumab) therapies in pretreated NSCLC patients.
- Concludes that PD-1 inhibitors may have superior efficacy, but PD-L1 inhibitors offer a better safety profile.
- Provides clinical guidance for treatment selection in advanced lung cancer.
6. Dendritic cell/cytokine‐induced killer cell‐based immunotherapy in lung cancer: What we know and future landscape
Authors: M Mohsenzadegan, RW Peng, R Roudi
Journal: Journal of Cellular Physiology
Publication Year: 2020
Summary:
- Discusses dendritic cell-based immunotherapy and cytokine-induced killer (CIK) cell therapy in lung cancer treatment.
- Evaluates current clinical trials and preclinical studies, exploring their potential as alternative or combinatory immunotherapies.
- Offers a comprehensive perspective on cell-based therapies in oncology.
Conclusion
Dr. Raheleh Roudi is a highly qualified researcher with outstanding contributions to cancer immunotherapy, nanoparticle-based drug delivery, and molecular medicine. Her publication record, interdisciplinary expertise, and global collaborations make her a strong contender for the Best Researcher Award. While increasing grant acquisition and clinical translation efforts could further elevate her impact, her extensive work in cancer biology and immunotherapy already demonstrates remarkable scientific excellence.